A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease
Latest Information Update: 30 Jul 2020
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Jun 2019 Results published in the Journal of Hepatology
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2018 According to Gilead Sciences media release,dat from this study will be presented at The Liver Meeting 2018